4.3 Article

Clinical characteristics of COVID-19 infection in chronic obstructive pulmonary disease: a multicenter, retrospective, observational study

期刊

JOURNAL OF THORACIC DISEASE
卷 12, 期 5, 页码 1811-+

出版社

AME PUBL CO
DOI: 10.21037/jtd-20-1914

关键词

Clinical characteristics; chronic obstructive pulmonary disease (COPD); coronavirus disease 2019 (COVID-19)

资金

  1. Nanshan Medical Development Foundation of Guangdong Province

向作者/读者索取更多资源

Background: Coronavirus disease 2019 (COVID-19) has been a global pandemic disease, with more than 4 million cases and nearly 300,000 deaths. Little is known about COVID-19 in patients with chronic obstructive pulmonary disease (COPD). We aimed to evaluate the influence of preexisting COPD on the progress and outcomes of COVID-19. Methods: This was a multicenter, retrospective, observational study. We enrolled 1,048 patients aged 40 years and above, including 50 patients with COPD and 998 patients without COPD, and with COVID-19 confirmed via high-throughput sequencing or real-time reverse transcription-polymerase chain reaction, between December 11, 2019 and February 20, 2020. We collected data of demographics, pathologic test results, radiologic imaging, and treatments. The primary outcomes were composite endpoints determined by admission to an intensive care unit, the use of mechanical ventilation, or death. Results: Compared with patients who had COVID-19 but not COPD, those with COPD had higher rates of fatigue (56.0% vs. 40.2%), dyspnea (66.0% vs. 26.3%), diarrhea (16.0% vs. 3.6%), and unconsciousness (8.0% vs. 1.7%) and a significantly higher proportion of increased activated partial thromboplastin time (23.5% vs. 5.2%) and D-dimer (65.9% vs. 29.3%), as well as ground-glass opacities (77.6% vs. 60.3%), local patchy shadowing (61.2% vs. 41.4%), and interstitial abnormalities (51.0% vs. 19.8%) on chest computed tomography. Patients with COPD were more likely to develop bacterial or fungal coinfection (20.0% vs. 5.9%), acute respiratory distress syndrome (ARDS) (20.0% vs. 7.3%), septic shock (14.0% vs. 2.3%), or acute renal failure (12.0% vs. 1.3%). Patients with COPD and COVID-19 had a higher risk of reaching the composite endpoints [hazard ratio (HR): 2.17, 95% confidence interval (CI): 1.40-3.38; P=0.001] or death (HR: 2.28, 95% CI: 1.15-4.51; P=0.019), after adjustment. Conclusions: In this study, patients with COPD who developed COVID-19 showed a higher risk of admission to the intensive care unit, mechanical ventilation, or death.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Virology

Development of SARS-CoV-2 animal vaccines using a stable and efficient NDV expression system

Lei He, Jiaying Zhong, Guichang Li, Zhengfang Lin, Peijing Zhao, Chuhua Yang, Hairong Wang, Yuhao Zhang, Xiaoyun Yang, Zhongfang Wang

Summary: This study established an efficient and stable system using Newcastle disease virus (NDV) as a vector to generate vaccines against SARS-CoV-2 in animals. The results showed that intramuscular immunization with rNDV-S induced the highest level of binding and neutralizing antibodies, as well as a strong S-specific T-cell response in mice. Intranasal immunization with rNDV-S1 mainly elicited a robust T-cell response. Overall, the NDV-vectored vaccine candidates were able to induce profound humoral and cellular immunity.

JOURNAL OF MEDICAL VIROLOGY (2023)

Article Medicine, Research & Experimental

Genetic screening of MMP1 as a potential pathogenic gene in chronic obstructive pulmonary disease

Erkang Yi, Weitao Cao, Jiahuan Zhang, Biting Lin, Zihui Wang, Xiaoyu Wang, Ge Bai, Xinyue Mei, ChengShu Xie, Jing Jin, Xinyuan Liu, Haiqing Li, Fan Wu, Zhiwei Lin, Ruiting Sun, Bing Li, Yumin Zhou, Pixin Ran

Summary: This study aims to identify and validate the key genes driving the development of chronic obstructive pulmonary disease (COPD) through bioinformatics analysis and experimental validation. Results revealed a series of potential pathogenic genes of COPD, among which MMP1 was the most likely gene responsible for the progression of COPD. MMP1 is significantly related to inflammatory effects and cilia function in human bronchial epithelial cells.

LIFE SCIENCES (2023)

Article Chemistry, Multidisciplinary

Efficient Targeted Delivery of Bifunctional Circular Aptamer-ASO Chimera to Suppress the SARS-CoV-2 Proliferation and Inflammation

Gang Yang, Shengnan Zhang, William Song, Xia Bai, Ling Li, Fatao Luo, Yiran Cheng, Diyue Wang, Yanqun Wang, Jiantao Chen, Jincun Zhao, Yongyun Zhao

Summary: A dual-function circular aptamer-ASO chimera (circSApt-NASO) is designed to suppress SARS-CoV-2 replication and inflammation, providing a potential therapy for COVID-19.
Letter Immunology

Heterologous Omicron-adapted vaccine as a secondary booster promotes neutralizing antibodies against Omicron and its sub-lineages in mice

Jianyang Liu, Qian He, Fan Gao, Lianlian Bian, Qian Wang, Chaoqiang An, Lifang Song, Jialu Zhang, Dong Liu, Ziyang Song, Lu Li, Yu Bai, Zhongfang Wang, Zhenglun Liang, Qunying Mao, Miao Xu

Summary: Over one billion people have received 2-3 dosages of an inactivated COVID-19 vaccine for basic immunization. The necessity of a booster dose to protect against the Omicron variant is still debated. In this study, researchers tested different vaccine platforms in mice and found that Omicron-adapted inactivated viral vaccines generated a neutralizing antibody response against Omicron. Heterologous immunization with COVID-19 vaccines based on different platforms also significantly increased cross-neutralizing antibody levels against Omicron and its sub-lineages. The findings suggest that Omicron-adapted vaccines based on heterologous platforms should be prioritized in future COVID-19 vaccination strategies.

EMERGING MICROBES & INFECTIONS (2023)

Article Cell Biology

Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5

Yanqun Wang, An Yan, Deyong Song, Chuangchuang Dong, Muding Rao, Yuanzhu Gao, Ruxi Qi, Xiaomin Ma, Qiaoping Wang, Hongguang Xu, Hong Liu, Jing Han, Maoqin Duan, Shuo Liu, Xiaoping Yu, Mengqi Zong, Jianxia Feng, Jie Jiao, Huimin Zhang, Min Li, Beibei Yu, Yanxia Wang, Fanhao Meng, Xiaodan Ni, Ying Li, Zhenduo Shen, Baiping Sun, Xin Shao, Haifeng Zhao, Yanyan Zhao, Rui Li, Yanan Zhang, Guangying Du, Jun Lu, Chunna You, Hua Jiang, Lu Zhang, Lan Wang, Changlin Dou, Zheng Liu, Jincun Zhao

Summary: Researchers isolated two neutralizing antibodies BA7208 and BA7125 from mice engineered to produce human antibodies. BA7125 showed broad neutralizing activity against all variants, while BA7208 was highly potent neutralizing against all tested SARS-CoV-2 variants except Mu. By combining BA7208 and BA7125, a biparatopic antibody BA7208/7125 that neutralized all tested variants was generated. Cryo-electron microscopy structure analysis showed that the contact residues of these antibodies were conserved and had minimal interactions with mutational residues in RBD of current variants. In addition, BA7208/7125 demonstrated potent therapeutic efficacy against Omicron BA.1 and BA.2 in mice and could be used for effective prophylaxis.

CELL DISCOVERY (2023)

Article Infectious Diseases

Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial

Jun -Dong Wu, Jing-Xin Li, Jian Liu, Hao-Meng Wang, Guang-Hui Zhou, Jin Li, Dou Wu, Xiang Chen, Yan Feng, Xiao-Yuan Qi, Xue Wang, Jin-Bo Gou, Tie-Liang Ma, Xiao-Yun Yang, Li-Feng Xu, Peng Wan, Tao Zhu, Zhong-Fang Wang, Feng-Cai Zhu

Summary: This study aimed to assess the safety, immunogenicity, and efficacy of heterologous vaccination with the mRNA vaccine CS-2034 compared to the inactivated vaccine BBIBP-CorV as a fourth dose. The results showed that heterologous boosting with CS-2034 induced higher immune responses and protection against the SARS-CoV-2 omicron variant compared to homologous boosting.

LANCET INFECTIOUS DISEASES (2023)

Article Critical Care Medicine

Safety and immunogenicity of heterologous boosting with orally aerosolised or intramuscular Ad5-nCoV vaccine and homologous boosting with inactivated vaccines (BBIBP-CorV or CoronaVac) in children and adolescents: a randomised, open-label, parallel-controlled, non- inferiority, single-centre study

Tao Huang, Sheng Zhang, De -Fang Dai, Bu-Sen Wang, Lu Zhuang, Hai-Tao Huang, Zhong-Fang Wang, Jun-Shi Zhao, Qiu-Ping Li, Shi-Po Wu, Xue Wang, Wen-Dan Zhang, Zheng-Hao Zhao, Hao Li, Yan-Ping Zhang, Xiu-Liang Yang, Xin-Yang Jiang, Jin-Bo Gou, Li-Hua Hou, Li -Dong Gao, Zhi-Chun Feng

Summary: This study aimed to assess the safety and immunogenicity of heterologous booster immunisation with orally administered AAd5 vaccine in children and adolescents who had received two doses of inactivated vaccine. The results showed that AAd5 vaccine is safe and highly immunogenic against ancestral SARS-CoV-2 Wuhan-Hu-1 in children and adolescents.

LANCET RESPIRATORY MEDICINE (2023)

Article Immunology

Establishment of national standard for anti-SARS-Cov-2 neutralizing antibody in China: The first National Standard calibration traceability to the WHO International Standard

Lidong Guan, Qunying Mao, Dejiang Tan, Jianyang Liu, Xuanxuan Zhang, Lu Li, Mingchen Liu, Zhongfang Wang, Feiran Cheng, Bopei Cui, Qian He, Qingzhou Wang, Fan Gao, Yiping Wang, Lianlian Bian, Xing Wu, Jifeng Hou, Zhenglun Liang, Miao Xu

Summary: Neutralizing antibody (NtAb) levels are crucial in evaluating SARS-CoV-2 vaccines. The establishment of a unified WHO International Standard (IS) is important for accurate calibration of NtAb detection assays. The Chinese National Standard (NS) and WHO IS were developed in 2020, and a second-generation NS is urgently needed. Samples 33 and 66-99 have been developed as candidate NSs to minimize systematic errors and differences between Neut and PsN methods. Sample 66-99 has been approved as the second-generation NS with calibrated units for accurate NtAb testing.

FRONTIERS IN IMMUNOLOGY (2023)

Review Immunology

SARS-CoV-2 epitope-specific T cells: Immunity response feature, TCR repertoire characteristics and cross-reactivity

Gang Yang, Junxiang Wang, Ping Sun, Jian Qin, Xiaoyun Yang, Daxiang Chen, Yunhui Zhang, Nanshan Zhong, Zhongfang Wang

Summary: This review summarizes the immune response features of immunodominant epitope-specific T cells targeting different SRAS-CoV-2 proteome structures after infection and vaccination, and analyzes the epitope immunodominance hierarchy in combination with multiple epitope-specific T cell attributes and TCR repertoire characteristics. The review also discusses the significant implications of cross-reactive T cells toward HCoVs, SRAS-CoV-2, and variants of concern, especially Omicron. This review may be essential for mapping the landscape of T cell responses toward SARS-CoV-2 and optimizing the current vaccine strategy.

FRONTIERS IN IMMUNOLOGY (2023)

Article Immunology

Proteomic profiling of single extracellular vesicles reveals colocalization of SARS-CoV-2 with a CD81/integrin-rich EV subpopulation in sputum from COVID-19 severe patients

Ruiting Sun, Yanling Cai, Yumin Zhou, Ge Bai, Airu Zhu, Panyue Kong, Jing Sun, Yimin Li, Yuefei Liu, Wenting Liao, Jiye Liu, Nan Cui, Jinsheng Xiang, Bing Li, Jincun Zhao, Di Wu, Pixin Ran

Summary: This study collected sputum samples from COVID-19 patients and healthy controls, and found that extracellular vesicles (EVs) derived from the sputum of patients carry the SARS-CoV-2 virus and can infect normal cells. In addition, EVs in the samples of COVID-19 patients express proteins related to SARS-CoV-2 infection. These findings demonstrate the involvement of EVs in virus infection and immune responses, and provide insights into the pathogenesis of SARS-CoV-2 infection and the possibility of developing nanoparticle-based antiviral drugs.

FRONTIERS IN IMMUNOLOGY (2023)

Article Biochemistry & Molecular Biology

Dicoumarol is an effective post-exposure prophylactic for SARS-CoV-2 Omicron infection in human airway epithelium

Yang Peng, Shi-ying Chen, Zhao-ni Wang, Zi-qing Zhou, Jing Sun, Gui-an Zhang, Jia Li, Lei Wang, Jin-cun Zhao, Xiao Xiao Tang, De-Yun Wang, Nan-shan Zhong

Summary: Repurposing existing drugs, such as dicoumarol (DCM), as a potential inhibitor for SARS-CoV-2 infection in airway epithelial cells (AECs) has been found to have potent antiviral activity against Omicron variants. Early treatment of DCM can effectively inhibit Omicron replication in AECs, and the expression of NAD(P)H quinone oxidoreductase 1 (NQO1), a known DCM target, is correlated with disease severity and virus copy levels. DCM treatment disrupts signaling pathways associated with SARS-CoV-2 disease outcomes and can help formulate novel treatment strategies for COVID-19.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2023)

Letter Biochemistry & Molecular Biology

Enhancement of SARS-CoV-2 vaccine-induced immunity by a Toll-like receptor 7 agonist adjuvant

Gen Li, Meixing Yu, Qiong Ke, Jing Sun, Yanwen Peng, Chuanfeng Xiong, Olivia Monteiro, Jincun Zhao, Andy Xiang

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2023)

Correction Biochemistry & Molecular Biology

Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants (vol 8, 167, 2023)

Qian Wang, Chenchen Yang, Li Yin, Jing Sun, Wei Wang, Hengchun Li, Zhengyuan Zhang, Si Chen, Bo Liu, Zijian Liu, Linjing Shi, Xiaolin Liu, Suhua Guan, Chunhua Wang, Linbing Qu, Ying Feng, Xuefeng Niu, Liqiang Feng, Jincun Zhao, Pingchao Li, Ling Chen, Nanshan Zhong

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2023)

Letter Biochemistry & Molecular Biology

Standardized neutralization antibody analytical procedure for clinical samples based on the AQbD concept

Jianyang Liu, Yu Bai, Mingchen Liu, Dejiang Tan, Jing Li, Zhongfang Wang, Zhenglun Liang, Miao Xu, Junzhi Wang, Qunying Mao

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2023)

Article Biochemistry & Molecular Biology

Phase-separated nucleocapsid protein of SARS-CoV-2 suppresses cGAS-DNA recognition by disrupting cGAS-G3BP1 complex

Sihui Cai, Chenqiu Zhang, Zhen Zhuang, Shengnan Zhang, Ling Ma, Shuai Yang, Tao Zhou, Zheyu Wang, Weihong Xie, Shouheng Jin, Jincun Zhao, Xiangdong Guan, Jianfeng Wu, Jun Cui, Yaoxing Wu

Summary: SARS-CoV-2 infection restricts the DNA recognition capacity of cGAS by its nucleocapsid protein, impairing the cGAS-induced IFN-I signaling. The study reveals that SARS-CoV-2 infection leads to the accumulation of released mtDNA, which triggers cGAS to activate IFN-I signaling.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2023)

暂无数据